Building a better analgesic: Multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 1, 2013, Pages 7-19

  Largent Milnes, T M ^a,d   Brookshire, S W ^a   Skinner Jr , D P ^a   Hanlon, K E ^a,c   Giuvelis, D ^c   Yamamoto, T ^b,e   Davis, P ^a   Campos, C R ^a   Nair, P ^b   Deekonda, S ^b   Bilsky, E J ^c   Porreca, F ^a,c   Hruby, V J ^b   Vanderah, T W ^a,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF NEW ENGLAND   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e AJINOMOTO CO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; MORPHINE SULFATE; TY 027; TYROSINE DETRO ALANYLGLYCYLPHENYLALANYLMETHIONYLPROLYLLEUCYLTRYPTOPHAN NH BN 2(CF3); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HYPERALGESIA; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALGESICS, OPIOID; ANIMALS; FERRETS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED ICR; MORPHINE; NALOXONE; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-1; SPINAL NERVES; TREATMENT OUTCOME;

EID: 84884616527     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205245     Document Type: Article

References (61)

1. Abbadie C, Brown JL, Mantyh PW, and Basbaum AI (1996) Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience 70:201-209.
2. Aicher SA, Punnoose A, and Goldberg A (2000) mu-Opioid receptors often colocalize with the substance P receptor (NK1) in the trigeminal dorsal horn. J Neurosci 20: 4345-4354.
3. Ananthan S, Kezar HS, 3rd, Carter RL, Saini SK, Rice KC, Wells JL, Davis P, Xu H, Dersch CM, and Bilsky EJ, et al. (1999) Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. J Med Chem 42:3527-3538.
4. Ariumi H, Saito R, Nago S, Hyakusoku M, Takano Y, and Kamiya H (2000) The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. Neurosci Lett 286:123-126.
5. Beggs S, Liu XJ, Kwan C, and Salter MW (2010) Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. Mol Pain 6:74.
6. Bountra C, Bunce K, Dale T, Gardner C, Jordan C, Twissell D, and Ward P (1993) Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 249:R3-R4.
7. Budai D, Khasabov SG, Mantyh PW, and Simone DA (2007) NK-1 receptors modulate the excitability of ON cells in the rostral ventromedial medulla. J Neurophysiol 97: 1388-1395.
8. Cahill CM and Coderre TJ (2002) Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain 95:277-285.
9. Cahill CM, Morinville A, Hoffert C, O'Donnell D, and Beaudet A (2003) Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: implications for pain control. Pain 101:199-208.
10. Centers for Disease Control and Prevention (CDC) (2011) Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 60:1487-1492.
11. Christie MJ (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154:384-396.
12. Cicero TJ, Ellis MS, and Surratt HL (2012) Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 367:187-189.
13. Commons KG (2010) Neuronal pathways linking substance P to drug addiction and stress. Brain Res 1314:175-182.
14. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ, Laird JM, Belmonte C, Cervero F, and Hunt SP (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392:394-397.
15. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, and Lambert DG (2009) Simultaneous targeting of multiple opioid receptors: a strategy to improve sideeffect profile. Br J Anaesth 103:38-49.
16. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, and Levy RM, et al. (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85(3, Suppl)S3-S14.
17. Echeverry S, Shi XQ, Rivest S, and Zhang J (2011) Peripheral nerve injury alters blood-spinal cord barrier functional and molecular integrity through a selective inflammatory pathway. J Neurosci 31:10819-10828.
18. Gadd CA, Murtra P, De Felipe C, and Hunt SP (2003) Neurokinin-1 receptorexpressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 23:8271-8280.
19. Gavériaux-Ruff C, Karchewski LA, Hever X, Matifas A, and Kieffer BL (2008) Inflammatory pain is enhanced in delta opioid receptor-knockout mice. Eur J Neurosci 27:2558-2567.
20. Gendron L, Pintar JE, and Chavkin C (2007) Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia. Neuroscience 150:807-817.
21. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, and Paulozzi LJ (2008) Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300:2613-2620.
22. Hargreaves R, Ferreira JC, Hughes D, Brands J, Hale J, Mattson B, and Mills S (2011) Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci 1222:40-48.
23. Hill RG (2000) NK1 (substance P) receptor antagonists-why are they not analgesic in humans? Sci 21:244-246.
24. Holzhäuer-Oitzl MS, Hasenöhrl R, and Huston JP (1988) Reinforcing properties of substance P in the region of the nucleus basalis magnocellularis in rats. Neuropharmacology 27:749-756.
25. Hylden JL and Wilcox GL (1982) Intrathecal opioids block a spinal action of substance P in mice: functional importance of both mu- and delta-receptors. Eur J Pharmacol 86:95-98.
26. Institute of Medicine (2011) Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research, The National Academies Press, Washington, DC.
27. Jensen TS and Finnerup NB (2009) Neuropathic pain treatment: a further step forward. Lancet 374:1218-1219.
28. King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP, Jr, Vanderah TW, Hunt SP, Hruby VJ, and Lai J, et al. (2005) Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 116:276-288.
29. Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, and Vanderah TW (2010) Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br J Pharmacol 161:986-1001.
30. Lenard NR, Daniels DJ, Portoghese PS, and Roerig SC (2007) Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur J Pharmacol 566:75-82.
31. Lessard A, Savard M, Gobeil F, Jr, Pierce JP, and Pickel VM (2009) The neurokinin-3 (NK3) and the neurokinin-1 (NK1) receptors are differentially targeted to mesocortical and mesolimbic projection neurons and to neuronal nuclei in the rat ventral tegmental area. Synapse 63:484-501.
32. Lu XF, Li YY, Wang CG, Wei JQ, Ye Y, Zhang LC, and Cao JL (2011) Substance P in the cerebrospinal fluid-contacting nucleus contributes to morphine physical dependence in rats. Neurosci Lett 488:188-192.
33. Lutz PE and Kieffer BL (2013) The multiple facets of opioid receptor function: implications for addiction. Curr Opin Neurobiol. doi:pii: S0959-4388(13)00053-6.10.1016/j.conb.2013.02.005.
34. Malcangio M, Ramer MS, Jones MG, and McMahon SB (2000) Abnormal substance P release from the spinal cord following injury to primary sensory neurons. Eur J Neurosci 12:397-399.
35. Maldonado R, Girdlestone D, and Roques BP (1993) RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci Lett 156:135-140.
36. Mantyh PW, Rogers SD, Honore P, Allen BJ, Ghilardi JR, Li J, Daughters RS, Lappi DA, Wiley RG, and Simone DA (1997) Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science 278:275-279.
37. Muñoz M and Coveñas R (2010) Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med 10:305-313.
38. Murtra P, Sheasby AM, Hunt SP, and De Felipe C (2000) Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405:180-183.
39. Nadal X, Baños JE, Kieffer BL, and Maldonado R (2006) Neuropathic pain is enhanced in delta-opioid receptor knockout mice. Eur J Neurosci 23:830-834.
40. Negus SS, Gatch MB, Mello NK, Zhang X, and Rice K (1998) Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J Pharmacol Exp Ther 286:362-375.
41. Paxinos G and Watson WC, eds, ed (1997) The Rat Brain in Stereotaxic Coordinates, Academic Press, Sydney.
42. Placenza FM, Fletcher PJ, Vaccarino FJ, and Erb S (2006) Effects of central neurokinin-1 receptor antagonism on cocaine- and opiate-induced locomotor activity and self-administration behaviour in rats. Pharmacol Biochem Behav 84: 94-101.
43. Powell KJ, Quirion R, and Jhamandas K (2003) Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur J Neurosci 18:1572-1583.
44. Richebe P, Cahana A, and Rivat C (2012) Tolerance and opioid-induced hyperalgesia. Is a divorce imminent? Pain 153:1547-1548.
45. Ripley TL, Gadd CA, De Felipe C, Hunt SP, and Stephens DN (2002) Lack of selfadministration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology 43:1258-1268.
46. Rivat C, Vera-Portocarrero LP, Ibrahim MM, Mata HP, Stagg NJ, De Felice M, Porreca F, and Malan TP (2009) Spinal NK-1 receptor-expressing neurons and descending pathways support fentanyl-induced pain hypersensitivity in a rat model of postoperative pain. Eur J Neurosci 29:727-737.
47. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, Kieffer BL, and Basbaum AI (2009) Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137:1148-1159.
48. Schramm CL and Honda CN (2010) Co-administration of δ- and μ-opioid receptor agonists promotes peripheral opioid receptor function. Pain 151:763-770.
49. Seybold VS, Hylden JL, and Wilcox GL (1982) Intrathecal substance P and somatostatin in rats: behaviors indicative of sensation. Peptides 3:49-54.
50. Substance Abuse and Mental Health Services Administration (2010) Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. http://www.samhsa.gov/data/NSDUH/2k10NSDUH/2k10Results.htm (accessed June 15, 2012).
51. Szücs M, Boda K, and Gintzler AR (2004) Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen- Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling. J Pharmacol Exp Ther 310:256-262.
52. Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, and Varga EV (2012) Tachykinin NK1 receptor antagonist coadministration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. Eur J Pharmacol 684:64-70.
53. Vanderah TW (2010) Delta and kappa opioid receptors as suitable drug targets for pain. Clin J Pain 26 (Suppl 10):S10-S15.
54. Vanderah TW, Ossipov MH, Lai J, Malan TP, Jr, and Porreca F (2001) Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 92:5-9.
55. Vera-Portocarrero LP, Ossipov MH, Lai J, King T, and Porreca F (2011) Descending facilitatory pathways from the rostroventromedial medulla mediate naloxoneprecipitated withdrawal in morphine-dependent rats. J Pain 12:667-676.
56. Vera-Portocarrero LP, Zhang ET, King T, Ossipov MH, Vanderah TW, Lai J, and Porreca F (2007) Spinal NK-1 receptor expressing neurons mediate opioidinduced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain 129:35-45.
57. Wan Q, Douglas SD, Wang X, Kolson DL, O'Donnell LA, and Ho WZ (2006) Morphine upregulates functional expression of neurokinin-1 receptor in neurons. J Neurosci Res 84:1588-1596.
58. Woodcock J, Witter J, and Dionne RA (2007) Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev Drug Discov 6:703-710.
59. Yamamoto T, Nair P, Davis P, Ma S-W, Navratilova E, Moye S, Tumati S, Lai J, Vanderah TW, and Yamamura HI, et al. (2007) Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem 50:2779-2786.
60. Yamamoto T, Nair P, Ma S-W, Davis P, Yamamura HI, Vanderah TW, Porreca F, Lai J, and Hruby VJ (2009) The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. Bioorg Med Chem 17: 7337-7343.
61. Yu YJ, Arttamangkul S, Evans CJ, Williams JT, and von Zastrow M (2009) Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of mu-opioid receptors in CNS neurons. J Neurosci 29:222-233.